Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RESEARCH TOOLSreports
Holding RARE?
Track your performance easily
RARE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$31.52 - $60.37
Previous Close$58.49
Volume495.34K
Average Volume (3M)787.34K
Market Cap
$5.39B
Enterprise Value$4.63B
Total Cash (Recent Filing)$763.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Oct 29, 2024EPS Estimate
-$1.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.29
Shares Outstanding92,165,190
10 Day Avg. Volume610,744
30 Day Avg. Volume787,340
Standard Deviation0.14
R-Squared0.04
Alpha0.00363
Financial Highlights & Ratios
Price to Book (P/B)12.30
Price to Sales (P/S)11.20
Price to Cash Flow (P/CF)-17.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.61
Enterprise Value/Gross Profit11.89
Enterprise Value/Ebitda-18.52
Forecast
1Y Price Target
$85.64Price Target Upside48.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Ultragenyx Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsUpdated data from their Phase 2 study testing setrusumab in osteogenesis imperfecta (OI) continue to demonstrate a meaningful reduction in fracture rate and improvement of the effects on both BMD and Z-score.
Financial PerformanceUltragenyx beats financial expectations and raises guidance, which should lead to near-term pop in shares.
Pipeline ProgressUltragenyx has completed enrollment of the pivotal Phase 3 portion of the ORBIT study as well as the open-label COSMIC trial.
Bears Say
Commercial ViabilityBears have pointed to some uncertainty on the commercial opportunity.
Market UncertaintySome uncertainty regarding a potential placebo response will likely remain an overhang on the program until the Ph.3 data is seen.
Safety ConcernsThe AE of lower limb weakness has been associated with GTX-102 but has been deemed transient; no patients have discontinued study due to this.
---
Ownership Overview
8.86% Insiders
32.42% Mutual Funds
52.88% Other Institutional Investors
5.84% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $31.52 and its highest was $60.37 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Currently, no data Available
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is Oct 29, 2024 which is in 40 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Aug 01, 2024. The company reported -$1.52 earnings per share for the quarter, beating the consensus estimate of -$1.661 by $0.141.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -$1.47.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 92,165,190 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$1.52 in its last earnings report, beating expectations of -$1.661. Following the earnings report the stock price went up 14.315%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Among the largest hedge funds holding Ultragenyx Pharmaceutical’s share is Sands Capital Management LLC. It holds Ultragenyx Pharmaceutical’s shares valued at 220M.
---
Ultragenyx Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$85.64 (48.42% Upside)
$85.64 (48.42% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.22%
12-Months-Change
Fundamentals
Return on Equity
-208.43%
Trailing 12-Months
Asset Growth
23.42%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
---
RARE Company Deck
---
RARE Earnings Call
Q2 2024
0:00 / 0:00
---
RARE Stock 12 Month Forecast
Average Price Target
$85.64
▲(48.42% Upside)
Technical Analysis
Best Analysts Covering RARE
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+25.54%
assigned a buy rating 2 months ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +25.54% per trade.
---